Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs

North West London
15 September 2014 13:01



South West
16 September 2014 16:07



North West London
26 September 2014 15:33


Exclusive vacancies may not be shown here, please contact Matthew on +44 1494 818 054 or matthew@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Matthew Moxon
Account Manager
matthew@zenopa.com
+44 1494 818 054

Testimonials
I have just secured my first position within the highly competitive medical sales industry, and I definitely could not have done it without the team at Zenopa's help.
Avril, 2012

Biomet sources leak list of IPO underwriters

27 February 2014 13:13 in Medical Company Financials


Biomet sources leak list of IPO underwritersBiomet will return to public ownership with an initial public offering (IPO) underwritten by Bank of America Merrill Lynch, Goldman Sachs and JPMorgan Chase & Co, according to people familiar with the matter.

The sources, who asked not to be named, told Reuters on February 26th the IPO would be held in the first half of 2014.

Biomet was acquired by a private equity consortium in 2007 for $11.4 billion (6.8 billion pounds), not long before the global financial crisis dealt a huge blow to the medical devices sector, causing patients to delay surgery and joint replacements.

The Warsaw, Indiana-based manufacturer, which was founded in 1977 and markets products such as dental implants and artificial hip joints, hopes the forthcoming offering will raise more than $1 billion.

Its sales reached $3 billion in the financial year ended May 2013 - an eight percent year-on-year increase - while adjusted net income rose 46 percent to $368 million.ADNFCR-8000103-ID-801698448-ADNFCR

Other news stories from 27/02/2014

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd